JPRN-UMIN000000756已完成未知
Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgery - CAPTAIN Study
Graduate School of Medicine, Tohoku University0 个研究点目标入组 150 人开始时间: 2007年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with contraindication for Candesartan Patients with allergic reaction to Candesartan Pregnant or potentially pregnant Patients who did not consent to the study Patients under 20 years of age Others who are not suitable to the enrollment from the physician's point of view
研究者
相似试验
已完成
不适用
Candesartan in renal artery stenosis (CARLAS)Circulatory SystemRenal artery stenosisISRCTN35143689AstraZeneca (Sweden)200
进行中（未招募）
不适用
Candesartan added Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters.An open, non-controlled and multicentre trialHeart failureEUCTR2004-003962-14-DETakeda Pharma GmbH
进行中（未招募）
不适用
Candesartan added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months. - CAN-DHFSymptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patientsMedDRA version: 9.1Level: LLTClassification code 10019279Term: Heart failureMedDRA version: 9.1Level: LLTClassification code 10052337Term: Diastolic dysfunctionEUCTR2007-003070-26-DETakeda Pharma GmbH
已完成
3 期
Candesartan in the Prevention of Relapsing Atrial FibrillationAtrial FibrillationNCT00130975Asker & Baerum Hospital200
尚未招募
不适用
The prevention effect of ARB(Candesartan) upon chronic heart failure of the newly hemo-dialysis patientsJPRN-UMIN000000588Osaka University, Graduate School of Medicine, Devision of Nephrology50